Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • antidepressant

    - PMLiVE

    Johnson & Johnson files FDA application for Tremfya in psoriatic arthritis

    Approximately 125 million people globally are living with some form of psoriasis

    - PMLiVE

    Johnson & Johnson’s TAR-200 granted FDA priority review to treat bladder cancer

    An estimated 84,870 people will be diagnosed with bladder cancer in the US this year

    - PMLiVE

    Johnson & Johnson’s Tremfya granted EC approval to treat ulcerative colitis in adults

    More than 2.5 million people in Europe are living with the inflammatory bowel disease

    - PMLiVE

    J&J’s Stelara granted EC approval to treat Crohn’s disease in paediatric patients

    Approximately 25% of cases are diagnosed during childhood or adolescence

    - PMLiVE

    Johnson & Johnson’s Tremfya recommended by CHMP to treat Crohn’s disease

    Inflammatory bowel disease is estimated to affect nearly two million people across Europe

    - PMLiVE

    J&J shares overall survival results for Rybrevant/Lazcluze combination in lung cancer

    The regimen was approved by the MHRA earlier this month to treat EGFR-mutated NSCLC

    - PMLiVE

    Johnson & Johnson to invest more than $55bn in US over next four years

    The commitment marks a 25% increase to the company's US investments in the past four years

    - PMLiVE

    Johnson & Johnson’s Tremfya granted FDA approval to treat Crohn’s disease

    An estimated three million people in the US are affected by inflammatory bowel disease

    - PMLiVE

    J&J/Protagonist’s icotrokinra shows promise in phase 3 plaque psoriasis programme

    More than 125 million people worldwide are estimated to be living with the immune-mediated skin disease

    - PMLiVE

    J&J’s Lazcluze/Rybrevant combination granted MHRA approval for lung cancer

    Approximately 47,000 people are diagnosed with lung cancer every year in the UK

    - PMLiVE

    J&J receives three CHMP recommendations for immunology and oncology indications

    Tremfya, Stelara and Darzalex have been recommended for ulcerative colitis, Crohn’s disease and multiple myeloma, respectively

    - PMLiVE

    J&J’s subcutaneous Rybrevant receives positive CHMP opinion for advanced lung cancer

    The formulation significantly reduces administration time compared to the approved intravenous version

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links